(GILD) Gilead Sciences, Inc. Company Overview

What does Gilead Sciences do?

Gilead Sciences, Inc. is a Nasdaq-listed biopharmaceutical company focused on medicines for life-threatening diseases, especially HIV, viral hepatitis, COVID-19, cancer, cell therapy, and inflammation. The company describes its mission as discovering, developing, and delivering innovative therapeutics for people with life-threatening diseases on its official company page. For research purposes, Gilead is not a diversified healthcare conglomerate; it is a specialty medicines business whose economics depend on exclusivity, clinical evidence, physician adoption, payer access, and replacement of aging franchises.

Which therapy areas define the business?

The company’s FY2025 Form 10-K shows a one-segment business that is economically diversified by product family rather than by formal operating division. HIV remains the core profit engine, liver disease is a mature but still meaningful cash contributor, oncology is the strategic diversification effort, and Veklury has become a lower, more volatile COVID-19 revenue stream after pandemic demand normalized. That structure matters because a student analyzing Gilead should not treat every revenue dollar as equally durable: HIV maintenance and prevention products have different patent, reimbursement, and switching-cost characteristics than cell therapy or pandemic-driven antivirals.

How does Gilead Sciences make money?

Gilead makes money mainly by selling branded prescription medicines to wholesalers, hospitals, pharmacies, clinics, and other healthcare channels. The company also reports smaller royalty, contract, and other revenue, but product sales dominate the model. In FY2025, total revenue was $29.4B, of which product sales were $28.9B and royalty, contract, and other revenue was $527M. Product economics are then reduced by rebates, chargebacks, discounts, returns, and patient-access programs; in FY2025, gross-to-net deductions were $20.0B, equal to about 41% of gross product sales, so payer contracting is a core financial variable rather than a back-office detail.

Which products carry the revenue base?

The product mix is unusually concentrated even for a large pharmaceutical company. In FY2025, HIV products generated $20.8B of product sales, while Biktarvy alone generated $14.3B. Descovy added $2.8B, liver disease products generated $3.2B, oncology products generated $3.2B, cell therapy generated $1.8B, and Veklury contributed $911M. This explains why investors watch not only total revenue growth, but also the composition of revenue: a dollar of Biktarvy revenue has a different risk profile from a dollar of Veklury revenue or a newly launched specialty-liver product.

Which products matter most to Gilead’s current story?

The current story is portfolio management. HIV funds the company, while oncology, liver disease, and long-acting prevention determine whether Gilead can reduce concentration risk over time. The company’s official therapeutic-areas overview frames the business around almost 40 years of work in HIV, viral hepatitis, emerging viruses, and cancer. That history explains why Gilead has the infrastructure and credibility to launch specialist medicines, and why valuation depends on whether new products can offset eventual HIV exclusivity pressure.

Why is HIV both the engine and the concentration risk?

HIV is attractive because it is a chronic market with high clinical need, established treatment guidelines, and real switching costs when a regimen works. It is also risky because a single therapy area generated roughly 72% of FY2025 product sales. Gilead’s June 2025 approval of Yeztugo, a twice-yearly lenacapavir HIV prevention option, shows the strategic direction: defend HIV leadership not only with daily oral therapy, but also with long-acting prevention formats that can expand the addressable market and deepen the franchise.

What is changing outside HIV?

Outside HIV, the watch items are more mixed. Trodelvy grew in FY2025 and Q1 2026, while cell therapy declined in both periods due to competitive headwinds. Liver disease added a newer growth signal through Livdelzi, and in May 2026 the company announced FDA accelerated approval of Hepcludex for chronic hepatitis delta virus. For a DCF model, these non-HIV assets are important less because they already rival Biktarvy, and more because they indicate whether the company can create a second and third durable growth leg.

What does Gilead’s latest quarter show?

The latest official quarter shows a company still growing from its HIV base while actively paying for pipeline expansion. In Q1 2026, Gilead reported total revenue of $7.0B, up 4% year over year, product sales of $6.9B, and product sales excluding Veklury of $6.8B, up 8%. The same Q1 2026 financial-results release reported GAAP diluted EPS of $1.61 and non-GAAP diluted EPS of $2.03. The plain-English read is that core product demand improved, but acquisition-related investment and debt repayment are now part of the 2026 financial story.

What changed in sales and margins?

The strongest Q1 2026 signal was not Veklury. Excluding Veklury, product sales grew 8% year over year, with HIV product sales up 10% to $5.030B and Trodelvy up 37% to $402M. Product gross margin improved to 79.2% in Q1 2026 from 76.7% in Q1 2025, while non-GAAP product gross margin improved to 87.5% from 85.5%. That improvement matters because product mix, manufacturing cost, royalties, and inventory charges can change reported pharmaceutical margins quickly.

How did cash and balance sheet move?

Q1 2026 operating cash flow was $2.544B, and capital expenditures were $117M, implying free cash flow of about $2.427B for the quarter. Cash and marketable debt securities declined from $10.6B at December 31, 2025 to $8.6B at March 31, 2026 because the company repaid $2.8B of debt, paid $1.0B of dividends, and repurchased $419M of shares, partially offset by cash generated from operations.

What strategic turning points still shape Gilead today?

Gilead’s history is best understood as a sequence of therapeutic-area bets. The company built a leading antiviral franchise, used hepatitis C cash flows to expand, acquired platforms in oncology and specialty medicine, and is now reinvesting into long-acting HIV, cell therapy, antibody-drug conjugates, and inflammation. The common theme is clear: management is trying to convert scientific specialization into durable commercial categories before older products lose exclusivity or competitive momentum.

1. 1987 onward
   Gilead’s antiviral roots established the scientific identity that still shapes its HIV and liver disease franchises.
2. 2011
   The $11B Pharmasset agreement accelerated Gilead’s all-oral hepatitis C strategy and later helped create a major, though eventually declining, HCV cash-flow cycle.
3. 2017
   The $11.9B Kite acquisition moved Gilead into cell therapy and gave the company Yescarta and Tecartus as an oncology platform.
4. 2020
   Veklury became a COVID-19 revenue stream, creating temporary scale but also a revenue line tied to hospitalization cycles rather than chronic usage.
5. 2024–2025
   Livdelzi and Yeztugo added newer specialty-liver and HIV prevention growth options, widening the commercial story beyond daily HIV treatment.
6. 2026
   The Arcellx acquisition and anticipated acquired IPR&D charges signaled a heavier reinvestment year aimed at strengthening oncology, inflammation, and future pipeline depth.

Why do acquisitions matter in this model?

Large pharmaceutical companies can build products internally, acquire late-stage assets, or use collaborations to share risk. Gilead uses all three, but acquisitions have repeatedly changed the company’s strategic direction. The April 2026 completion of the Arcellx acquisition for an implied equity value of about $7.8B illustrates the trade-off: near-term cash and earnings pressure can be acceptable if the acquired asset extends the growth runway in a therapeutic area where Gilead already wants a deeper position.

What gives Gilead a durable competitive advantage in HIV and specialty medicines?

Gilead’s moat is strongest where clinical evidence, physician trust, reimbursement access, manufacturing know-how, and patient persistence reinforce each other. In HIV, the company has a large installed base, major single-tablet regimens, and credibility with clinicians. In liver disease, it has a long record of antiviral development and specialist access. In oncology, the moat is less proven because competition is intense and clinical differentiation can change quickly when new data arrive.

Where is the moat strongest?

The strongest resource is the HIV franchise. Biktarvy’s FY2025 sales of $14.334B and Q1 2026 sales of $3.361B indicate scale that supports payer negotiations, clinical familiarity, lifecycle management, and cash generation. Long-acting lenacapavir prevention could extend that advantage if access, adherence, and reimbursement work at scale. In a VRIO-style analysis, the resource is valuable, difficult to replicate quickly, and embedded in commercial processes, although it is not immune to patent and policy risk.

Where is it less durable?

The moat is weaker where a product needs repeated clinical-data wins against fast-moving rivals. Cell therapy is the obvious example: Q1 2026 cell therapy sales declined 12% year over year to $407M, with Yescarta down 14% to $332M. That makes Kite a recovery-and-execution question: can next-generation assets, manufacturing execution, and new indications restore growth while treatment options multiply?

Who competes with Gilead Sciences?

Competition differs by therapy area. In HIV, Gilead competes against other branded regimens, long-acting prevention options, generics, and future pipeline entrants. In oncology, it competes against antibody-drug conjugates, checkpoint combinations, CAR-T products, bispecific antibodies, and other targeted therapies. In liver disease, older hepatitis C markets have generic and volume pressure, while newer specialty-liver categories are more dependent on regulatory approvals and evidence in narrower patient populations.

Which rivals pressure HIV, oncology, and liver disease?

A practical competitor map should focus on the mechanism of pressure. HIV pressure comes from regimen innovation, prevention alternatives, patent expirations, and payer decisions. Oncology pressure comes from trial data, label breadth, toxicity, manufacturing capacity, and physician adoption. Liver disease pressure comes from mature hepatitis C markets, specialty access, and evidence in conditions such as PBC and HDV.

How financially strong is Gilead Sciences?

Gilead is financially strong in cash generation, but not asset-light in the way a software company is. In FY2025, the company reported $29.443B of total revenue, $8.510B of net income attributable to Gilead, and $10.019B of operating cash flow. It also spent $5.799B on R&D, paid $4.003B in dividends, repurchased $1.922B of stock, and ended FY2025 with $24.937B of total debt net of issuance costs. That combination shows a mature pharmaceutical cash machine funding a large reinvestment program.

What do margins and cash conversion say?

The reported FY2025 product gross margin was 78.4%, but the more useful view is revenue-to-cash conversion. Gilead converted substantial earnings into FY2025 operating cash flow despite inventory, tax, and working-capital effects. With FY2025 capex of $563M, free cash flow by operating cash flow minus property and equipment purchases was about $9.456B.

How does leverage shape flexibility?

Gilead ended FY2025 with $7.564B of cash and cash equivalents, $3.042B of marketable debt securities, and $24.937B of total debt net. The company had a $2.5B revolving credit facility maturing in June 2029 with no borrowings outstanding at December 31, 2025. The balance sheet is not distressed, but the debt base and 2026 acquisition activity make cash deployment choices more consequential.

Who owns Gilead stock, and why does governance matter?

Gilead has a one-share-one-vote public-company ownership profile with no founder-controlled dual-class structure. The latest 2026 proxy statement shows a shareholder base led by large institutional holders. This matters because capital allocation, executive compensation, and pipeline risk are interpreted through institutional governance rather than founder control.

Does any one holder control the company?

No single owner in the proxy table controls Gilead. Daniel O’Day served as Chairman and CEO, and the proxy identifies Anthony Welters as Lead Independent Director. The governance implication is that investor oversight comes through the board, say-on-pay voting, engagement with large holders, and compensation design. In fall 2025, the company contacted holders representing 58% of shares and met with holders representing 42%, which signals active institutional dialogue.

What incentives are management paid on?

The 2026 proxy links executive incentives to both financial and strategic goals. For 2025, the annual cash incentive corporate performance framework was weighted 60% to financial results and 40% to pipeline, product, and people measures. Long-term incentives included performance shares tied to relative total shareholder return and adjusted EPS growth. That matters because management is being evaluated not only on near-term earnings, but also on product execution and longer-term value creation.

What risks could change Gilead’s outlook?

Gilead’s risk profile is specific to innovative pharmaceuticals: product concentration, patent and exclusivity cliffs, regulatory outcomes, reimbursement pressure, clinical-trial failure, manufacturing complexity, competition, acquisition integration, and safety findings. The filing language is not abstract. The company’s own 2026 outlook says product sales excluding Veklury are expected to be bolstered by HIV demand but partially offset by U.S. policy developments and cell-therapy competitive headwinds. That is the risk map in one sentence: durable HIV demand is carrying the business while policy, competition, and pipeline execution decide how much of that durability converts into long-term value.

Which risks are most material for students and investors?

The biggest analytical risk is not one bad quarter. It is the possibility that established HIV cash flows remain strong but new investments fail to create enough replacement value. That would leave Gilead with a profitable but increasingly concentrated base. Conversely, if Yeztugo, specialty liver products, Trodelvy, and acquired oncology or inflammation assets scale successfully, the company’s revenue mix can become more balanced without abandoning the antiviral franchise that made it important.

Why does Gilead’s business model matter for valuation?

Gilead is a DCF-sensitive company because present cash flows are strong, but terminal value depends on future product replacement. A valuation model should separate the established HIV and liver/cell therapy base from pipeline-driven optionality. The key operating assumptions are not only revenue growth and operating margin. They also include patent timing, gross-to-net deductions, clinical probability of success, launch curves, R&D intensity, business-development spending, and the cash cost of maintaining the dividend while funding acquisitions.

Which assumptions matter most?

A base case should model core HIV growth, Veklury normalization, oncology scale, and pipeline conversion separately. Operating margin should reflect the difference between product gross margin and the heavy R&D and SG&A structure required to commercialize specialty medicines. Free cash flow should start with operating cash flow and subtract capital expenditures, but the analyst should also consider whether business-development payments are recurring economic reinvestment rather than one-time noise.

What is the key takeaway from Gilead Sciences analysis?

Gilead is a high-cash-flow pharmaceutical company whose strategic question is unusually clear. The business is important because it has helped define HIV and antiviral medicine, still produces very large cash flows, and has the financial capacity to invest in new therapeutic areas. The constraint is that the same HIV concentration that supports current earnings also creates long-term replacement pressure. Therefore, the company should be analyzed as a cash-generating base business plus a portfolio of pipeline and acquisition bets, not as a simple revenue-growth story.